메뉴 건너뛰기




Volumn 7, Issue 6, 2007, Pages 547-555

Dipeptidyl peptidase IV inhibitors: The next generation of new promising therapies for the management of type 2 diabetes

Author keywords

Diabetes; DPP IV; GIP; GLP 1; Incretins

Indexed keywords

6 [[2 [[2 (2 CYANO 1 PYRROLIDINYL) 2 OXOETHYL]AMINO]ETHYL]AMINO]NICOTINONITRILE; ANTIDIABETIC AGENT; DIPEPTIDYL PEPTIDASE IV; DIPEPTIDYL PEPTIDASE IV INHIBITOR; FE 999011; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; HEMOGLOBIN A1C; INCRETIN; ISOLEUCINE THIAZOLIDIDE; LIPID; LIRAGLUTIDE; METFORMIN; P 93 01; PLACEBO; PSN 9301; SAXAGLIPTIN; SITAGLIPTIN; SYR 322; UNCLASSIFIED DRUG; VILDAGLIPTIN;

EID: 33947672273     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/156802607780091019     Document Type: Review
Times cited : (63)

References (107)
  • 1
    • 2342466734 scopus 로고    scopus 로고
    • Global Prevalence of Diabetes: Estimates for the year 2000 and projections for 2030
    • Wild, S.; Roglic, G.; Green, A.; Sicree, R.; King, H. Global Prevalence of Diabetes: Estimates for the year 2000 and projections for 2030. Diabetes Care 2004, 27, 1047-1053.
    • (2004) Diabetes Care , vol.27 , pp. 1047-1053
    • Wild, S.1    Roglic, G.2    Green, A.3    Sicree, R.4    King, H.5
  • 2
    • 9444244529 scopus 로고    scopus 로고
    • Gastric inhibitory polypeptide and glucagon-like peptide- 1 in the pathogenesis of type 2 diabetes
    • Nauck, M. A.; Baller, B.; Meier, J. J. Gastric inhibitory polypeptide and glucagon-like peptide- 1 in the pathogenesis of type 2 diabetes. Diabetes 2004, 53(Suppl. 3), S190-S196.
    • (2004) Diabetes , vol.53 , Issue.SUPPL. 3
    • Nauck, M.A.1    Baller, B.2    Meier, J.J.3
  • 3
    • 0030831056 scopus 로고    scopus 로고
    • Nonfasting plasma glucose is a better marker of diabetic control than fasting plasma glucose in type 2 diabetes
    • Avignon, A.; Radauceanu, A.; Monnier, L. Nonfasting plasma glucose is a better marker of diabetic control than fasting plasma glucose in type 2 diabetes. Diabetes Care 1997, 20, 1822-1826.
    • (1997) Diabetes Care , vol.20 , pp. 1822-1826
    • Avignon, A.1    Radauceanu, A.2    Monnier, L.3
  • 4
    • 12944320328 scopus 로고    scopus 로고
    • Prediction of the risk of cardiovascular mortality using a score that includes glucose as a risk factor. The DECODE Study
    • Balkau, B.; Hu, G.; Qiao, Q.; Tuomilehto, J.; Borch-Johnsen, K.; Pyorala, K. Prediction of the risk of cardiovascular mortality using a score that includes glucose as a risk factor. The DECODE Study. Diabetologia 2004, 47, 2118-2128.
    • (2004) Diabetologia , vol.47 , pp. 2118-2128
    • Balkau, B.1    Hu, G.2    Qiao, Q.3    Tuomilehto, J.4    Borch-Johnsen, K.5    Pyorala, K.6
  • 5
    • 4544232468 scopus 로고    scopus 로고
    • Inhibitors of dipeptidyl peptidase IV: A novel approach for the prevention and treatment of type 2 diabetes?
    • Deacon, C. F.; Ahren, B.; Holst, J. J. Inhibitors of dipeptidyl peptidase IV: A novel approach for the prevention and treatment of type 2 diabetes? Expert Opin. Invest. Drugs 2004, 13, 1091-1102.
    • (2004) Expert Opin. Invest. Drugs , vol.13 , pp. 1091-1102
    • Deacon, C.F.1    Ahren, B.2    Holst, J.J.3
  • 6
    • 0034967893 scopus 로고    scopus 로고
    • The entero-insular axis in type 2 diabetes - Incretins as therapeutic agents
    • Creutzfeldt, W. The entero-insular axis in type 2 diabetes - incretins as therapeutic agents. Exp. Clin. Endocrinol. Diabetes 2001, 109(Suppl. 2), S288-S303.
    • (2001) Exp. Clin. Endocrinol. Diabetes , vol.109 , Issue.SUPPL. 2
    • Creutzfeldt, W.1
  • 8
    • 0028953577 scopus 로고
    • Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo
    • Deacon, C. F.; Johnsen, A. H.; Holst, J. J. Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J. Clin. Endocrinol. Metabol. 1995, 80, 952-957.
    • (1995) J. Clin. Endocrinol. Metabol. , vol.80 , pp. 952-957
    • Deacon, C.F.1    Johnsen, A.H.2    Holst, J.J.3
  • 10
    • 0038759066 scopus 로고    scopus 로고
    • Deficiency of CD26 results in a change of cytokine and immunoglobin secretion after stimulation by pokeweed mitogen
    • Yan, S.; Marguet, D.; Dobers, J.; Reutter, W.; Fan, H. Deficiency of CD26 results in a change of cytokine and immunoglobin secretion after stimulation by pokeweed mitogen. Eur. J. Immunol. 2003, 33, 1519-1527.
    • (2003) Eur. J. Immunol. , vol.33 , pp. 1519-1527
    • Yan, S.1    Marguet, D.2    Dobers, J.3    Reutter, W.4    Fan, H.5
  • 11
    • 0034811909 scopus 로고    scopus 로고
    • Improved Glucose Tolerance via Enhanced Glucose-Dependent Insulin Secretion in Dipeptidyl Peptidase IV-Deficient Fischer Rats
    • Nagakura, T.; Yasuda, N.; Yamazaki, K.; Ikuta, H.; Yoshikawa, S.; Asano, O.; Tanaka, I. Improved Glucose Tolerance via Enhanced Glucose-Dependent Insulin Secretion in Dipeptidyl Peptidase IV-Deficient Fischer Rats. Biochem. Biophys. Res. Comm. 2001, 284, 501-506.
    • (2001) Biochem. Biophys. Res. Comm. , vol.284 , pp. 501-506
    • Nagakura, T.1    Yasuda, N.2    Yamazaki, K.3    Ikuta, H.4    Yoshikawa, S.5    Asano, O.6    Tanaka, I.7
  • 13
    • 4344675057 scopus 로고    scopus 로고
    • Therapeutic strategies based on glucagon-like peptide 1
    • Deacon, C. F. Therapeutic strategies based on glucagon-like peptide 1. Diabetes 2004, 53, 2181-2189.
    • (2004) Diabetes , vol.53 , pp. 2181-2189
    • Deacon, C.F.1
  • 14
    • 9444285818 scopus 로고    scopus 로고
    • Twelveand 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes
    • Ahren, B.; Gomis, R.; Standl, E.; Mills, D.; Schweizer, A. Twelveand 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes. Diabetes Care 2004, 27, 2874-2880.
    • (2004) Diabetes Care , vol.27 , pp. 2874-2880
    • Ahren, B.1    Gomis, R.2    Standl, E.3    Mills, D.4    Schweizer, A.5
  • 15
    • 2442482515 scopus 로고    scopus 로고
    • Inhibition of Dipeptidyl Peptidase-4 Reduces Glycemia, Sustains Insulin Levels, and Reduces Glucagon Levels in Type 2 Diabetes
    • Ahren, B.; Landin-Olsson, M.; Jansson, P.-A.; Svensson, M.; Holmes, D.; Schweizer, A. Inhibition of Dipeptidyl Peptidase-4 Reduces Glycemia, Sustains Insulin Levels, and Reduces Glucagon Levels in Type 2 Diabetes. J. Clin. Endocrinol. Metab. 2004, 89, 2078-2084.
    • (2004) J. Clin. Endocrinol. Metab. , vol.89 , pp. 2078-2084
    • Ahren, B.1    Landin-Olsson, M.2    Jansson, P.-A.3    Svensson, M.4    Holmes, D.5    Schweizer, A.6
  • 16
    • 23044487247 scopus 로고    scopus 로고
    • Improved meal-related beta-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1 year
    • Ahren, B.; Pacini, G.; Foley, J. E.; Schweizer, A. Improved meal-related beta-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1 year. Diabetes Care 2005, 28, 1936-1940.
    • (2005) Diabetes Care , vol.28 , pp. 1936-1940
    • Ahren, B.1    Pacini, G.2    Foley, J.E.3    Schweizer, A.4
  • 17
    • 0037787851 scopus 로고    scopus 로고
    • Dipeptidyl-Peptidase IV from Bench to Bedside: An Update on Structural Properties, Functions, and Clinical Aspects of the Enzyme DPP IV
    • Lambeir, A.-M.; Durinx, C.; Scharpe, S.; De Meester, I. Dipeptidyl-Peptidase IV from Bench to Bedside: An Update on Structural Properties, Functions, and Clinical Aspects of the Enzyme DPP IV. Crit. Rev. Clin. Lab. Sci. 2003, 40, 209-294.
    • (2003) Crit. Rev. Clin. Lab. Sci. , vol.40 , pp. 209-294
    • Lambeir, A.-M.1    Durinx, C.2    Scharpe, S.3    De Meester, I.4
  • 20
    • 22244482444 scopus 로고    scopus 로고
    • Dipeptidyl peptidase IV inhibitors for type 2 diabetes and metabolic syndrome
    • Wiedeman, P. E.; Trevillyan, J. M. Dipeptidyl peptidase IV inhibitors for type 2 diabetes and metabolic syndrome. Drug Discov. Today: Therapeutic Strategies 2005, 2, 143-149.
    • (2005) Drug Discov. Today: Therapeutic Strategies , vol.2 , pp. 143-149
    • Wiedeman, P.E.1    Trevillyan, J.M.2
  • 21
    • 33644892053 scopus 로고    scopus 로고
    • Inhibitors of Dipeptidyl Peptidase IV - Recent Advances and Structural Views
    • Hunziker, D.; Hennig, M.; Peters, J.-U. Inhibitors of Dipeptidyl Peptidase IV - Recent Advances and Structural Views. Curr. Top. Med. Chem. 2005, 5(16), 1623-1637.
    • (2005) Curr. Top. Med. Chem. , vol.5 , Issue.16 , pp. 1623-1637
    • Hunziker, D.1    Hennig, M.2    Peters, J.-U.3
  • 22
    • 0037234531 scopus 로고    scopus 로고
    • Therapeutic potential of dipeptidyl peptidase IV inhibitors for the treatment of type 2 diabetes
    • Drucker, J. Therapeutic potential of dipeptidyl peptidase IV inhibitors for the treatment of type 2 diabetes. Expert Opin. Invest. Drugs 2003, 12, 87-100.
    • (2003) Expert Opin. Invest. Drugs , vol.12 , pp. 87-100
    • Drucker, J.1
  • 23
    • 0036228243 scopus 로고    scopus 로고
    • Long-term treatment with the dipeptidyl peptidase IV inhibitor P32/98 causes sustained improvements in glucose tolerance, insulin sensitivity, hyperinsulinernia, and beta-cell glucose responsiveness in VDF fa/fa Zucker rats
    • Pospisilik, J. A.; Stafford, S. G.; Demuth, H. U.; Brownsey, R.; Parkhouse, W.; Finegood, D., T.; McIntosh, C. H. S.; Pederson, R. A. Long-term treatment with the dipeptidyl peptidase IV inhibitor P32/98 causes sustained improvements in glucose tolerance, insulin sensitivity, hyperinsulinernia, and beta-cell glucose responsiveness in VDF fa/fa Zucker rats. Diabetes 2002, 51, 943-950.
    • (2002) Diabetes , vol.51 , pp. 943-950
    • Pospisilik, J.A.1    Stafford, S.G.2    Demuth, H.U.3    Brownsey, R.4    Parkhouse, W.5    Finegood, D.T.6    McIntosh, C.H.S.7    Pederson, R.A.8
  • 24
    • 0000135759 scopus 로고    scopus 로고
    • Inhibition of dipeptidyl peptidase IV with NVP-DPP728 increases plasma GLP-I (7-36 amide) concentrations and improves oral glucose tolerance in obese Zucker rats
    • Balkan, B.; Kwasnik, L.; Miserendino, R.; Holst, J. J.; Li, X. Inhibition of dipeptidyl peptidase IV with NVP-DPP728 increases plasma GLP-I (7-36 amide) concentrations and improves oral glucose tolerance in obese Zucker rats. Diabetologia 1999, 42, 1324-1331.
    • (1999) Diabetologia , vol.42 , pp. 1324-1331
    • Balkan, B.1    Kwasnik, L.2    Miserendino, R.3    Holst, J.J.4    Li, X.5
  • 25
    • 0036312876 scopus 로고    scopus 로고
    • Chronic inhibition of circulating dipeptidyl peptidase TV by FE 999011 delays the occurrence of diabetes in male zucker diabetic fatty rats
    • Sudre, B.; Broqua, P.; White, R. B.; Ashworth, D.; Evans, D. M.; Haigh, R.; Junien, J.-L.; Aubert, M. L. Chronic inhibition of circulating dipeptidyl peptidase TV by FE 999011 delays the occurrence of diabetes in male zucker diabetic fatty rats. Diabetes 2002, 51, 1461-1469.
    • (2002) Diabetes , vol.51 , pp. 1461-1469
    • Sudre, B.1    Broqua, P.2    White, R.B.3    Ashworth, D.4    Evans, D.M.5    Haigh, R.6    Junien, J.-L.7    Aubert, M.L.8
  • 26
    • 0037267892 scopus 로고    scopus 로고
    • Enteroinsular axis of db/db mice and efficacy of dipeptidyl peptidase IV inhibition
    • Nagakura, T.; Yasuda, N.; Yamazaki, K.; Ikuta, H.; Tanaka, I. Enteroinsular axis of db/db mice and efficacy of dipeptidyl peptidase IV inhibition. Metab., Clin. Exp. 2003, 52, 81-86.
    • (2003) Metab., Clin. Exp. , vol.52 , pp. 81-86
    • Nagakura, T.1    Yasuda, N.2    Yamazaki, K.3    Ikuta, H.4    Tanaka, I.5
  • 27
    • 33644838045 scopus 로고    scopus 로고
    • The novel, xanthine-based, DPP-IV inhibitor NN7201 and LAF237 improve glucose tolerance, but do not prevent progression of diabetes in diabetic fatty rats
    • Rolin, N.; Nygaard, H.; Wilken, M.; Karstrup, A. B.; Carr, R. D. The novel, xanthine-based, DPP-IV inhibitor NN7201 and LAF237 improve glucose tolerance, but do not prevent progression of diabetes in diabetic fatty rats. Diabetes 2004, 53, A340.
    • (2004) Diabetes , vol.53
    • Rolin, N.1    Nygaard, H.2    Wilken, M.3    Karstrup, A.B.4    Carr, R.D.5
  • 29
    • 3342908639 scopus 로고    scopus 로고
    • Metformin Causes Reduction of Food Intake and Body Weight Gain and Improvement of Glucose Intolerance in Combination with Dipeptidyl Peptidase IV Inhibitor in Zucker fa/fa Rats
    • Yasuda, N.; Inoue, T.; Nagakura, T.; Yamazaki, K.; Kira, K.; Saeki, T.; Tanaka, I. Metformin Causes Reduction of Food Intake and Body Weight Gain and Improvement of Glucose Intolerance in Combination with Dipeptidyl Peptidase IV Inhibitor in Zucker fa/fa Rats. J. Pharmacol. Exp. Ther. 2004, 310, 614-619.
    • (2004) J. Pharmacol. Exp. Ther. , vol.310 , pp. 614-619
    • Yasuda, N.1    Inoue, T.2    Nagakura, T.3    Yamazaki, K.4    Kira, K.5    Saeki, T.6    Tanaka, I.7
  • 31
    • 2442482515 scopus 로고    scopus 로고
    • Inhibition of Dipeptidyl Peptidase-4 Reduces Glycemia, Sustains Insulin Levels, and Reduces Glucagon Levels in Type 2 Diabetes
    • Ahren, B.; Landin-Olsson, M.; Jansson, P.-A.; Svensson, M.; Holmes, D.; Schweizer, A. Inhibition of Dipeptidyl Peptidase-4 Reduces Glycemia, Sustains Insulin Levels, and Reduces Glucagon Levels in Type 2 Diabetes J. Clin. Endocrinol. Metab. 2004, 89, 2078-2084.
    • (2004) J. Clin. Endocrinol. Metab. , vol.89 , pp. 2078-2084
    • Ahren, B.1    Landin-Olsson, M.2    Jansson, P.-A.3    Svensson, M.4    Holmes, D.5    Schweizer, A.6
  • 32
    • 24944446982 scopus 로고    scopus 로고
    • Evidence for insulin independent suppression of glucagon secretion by LAF237
    • Jones-Leone, A.; Barilla, D.; He, Y.-L.; Ho, Y. Y.; Ligueros-Saylan, M. Evidence for insulin independent suppression of glucagon secretion by LAF237. Diabetologia 2004, suppl. 1, A289.
    • (2004) Diabetologia , Issue.SUPPL. 1
    • Jones-Leone, A.1    Barilla, D.2    He, Y.-L.3    Ho, Y.Y.4    Ligueros-Saylan, M.5
  • 37
    • 33947685633 scopus 로고    scopus 로고
    • Prosidion-Ltd Product Pipeline
    • Prosidion-Ltd Product Pipeline; http.//www.prosidion.com/products/ index.html; 2006.
    • (2006)
  • 38
    • 14044253388 scopus 로고    scopus 로고
    • The DP IV-inhibitor P93/01 improves glucose tolerance in humans with HbA1c greater than 6.0
    • Heins, J.; Glund, K.; Hoffmann, T.; Metzner, J.; Demuth, H.-U. The DP IV-inhibitor P93/01 improves glucose tolerance in humans with HbA1c greater than 6.0. Diabetes 2004, 53, A128.
    • (2004) Diabetes , vol.53
    • Heins, J.1    Glund, K.2    Hoffmann, T.3    Metzner, J.4    Demuth, H.-U.5
  • 42
    • 0031695395 scopus 로고    scopus 로고
    • Glucagon-like peptide 1 increases the period of postprandial satiety and slows gastric emptying in obese men
    • Nl̈und, E.; Gutniak, M.; Skogar, S.; Rössner, S.; Hellström, P. M. Glucagon-like peptide 1 increases the period of postprandial satiety and slows gastric emptying in obese men. Am. J Clin. Nutr. 1998, 68, 525-530.
    • (1998) Am. J Clin. Nutr. , vol.68 , pp. 525-530
    • Nl̈und, E.1    Gutniak, M.2    Skogar, S.3    Rössner, S.4    Hellström, P.M.5
  • 44
    • 19344375318 scopus 로고    scopus 로고
    • Intravenous infusion of glucagon-like peptide-1 potently inhibits food intake, sham feeding, and gastric emptying in rats
    • Chelikani, P. K.; Haver, A. C.; Reidelberger, R. D. Intravenous infusion of glucagon-like peptide-1 potently inhibits food intake, sham feeding, and gastric emptying in rats. Am. J. Physiol 2005, 288(6, Pt. 2), R1695-R1706.
    • (2005) Am. J. Physiol , vol.288 , Issue.6 PART 2
    • Chelikani, P.K.1    Haver, A.C.2    Reidelberger, R.D.3
  • 45
    • 15944419821 scopus 로고    scopus 로고
    • Distinct effects of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 on insulin secretion and gut motility
    • Miki, T.; Minami, K.; Shinozaki, H.; Matsumura, K.; Saraya, A.; Ikeda, H.; Yamada, Y.; Holst, J. J.; Scino, S. Distinct effects of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 on insulin secretion and gut motility. Diabetes 2005, 54, 1056-1063.
    • (2005) Diabetes , vol.54 , pp. 1056-1063
    • Miki, T.1    Minami, K.2    Shinozaki, H.3    Matsumura, K.4    Saraya, A.5    Ikeda, H.6    Yamada, Y.7    Holst, J.J.8    Scino, S.9
  • 46
    • 0037098976 scopus 로고    scopus 로고
    • GLP-1 and GLP-2 act in concert to inhibit fasted, but not fed, small bowel motility in the rat
    • Bozkurt, A.; Nälund, E.; Holst, J. I.; Hellström, P. M. GLP-1 and GLP-2 act in concert to inhibit fasted, but not fed, small bowel motility in the rat. Regul. Pept. 2002, 107, 129-135.
    • (2002) Regul. Pept. , vol.107 , pp. 129-135
    • Bozkurt, A.1    Nälund, E.2    Holst, J.I.3    Hellström, P.M.4
  • 47
    • 0035795230 scopus 로고    scopus 로고
    • The inhibitory mechanism of GLP-1, but not glucagon, on fasted gut motility is dependent on the L-arginine/nitric oxide pathway
    • Tolessa, T.; Nälund, E.; Hellström, P. M. The inhibitory mechanism of GLP-1, but not glucagon, on fasted gut motility is dependent on the L-arginine/nitric oxide pathway. Regul. Pept. 2001, 98, 33-40.
    • (2001) Regul. Pept. , vol.98 , pp. 33-40
    • Tolessa, T.1    Nälund, E.2    Hellström, P.M.3
  • 50
    • 0034951506 scopus 로고    scopus 로고
    • The effect of physiological levels of glucagon-like peptide-1 on appetite, gastric emptying, energy and substrate metabolism in obesity
    • Flint, A.; Raben, A.; Ersboll, A. K.; Holst, J. J.; Astrup, A. The effect of physiological levels of glucagon-like peptide-1 on appetite, gastric emptying, energy and substrate metabolism in obesity. Int. J. Obesity 2001, 25, 781-792.
    • (2001) Int. J. Obesity , vol.25 , pp. 781-792
    • Flint, A.1    Raben, A.2    Ersboll, A.K.3    Holst, J.J.4    Astrup, A.5
  • 51
    • 1642271221 scopus 로고    scopus 로고
    • Prandial subcutaneous injections of glucagon-like peptide-1 cause weight loss in obese human subjects
    • Nälund, E.; King, N.; Mansten, S.; Adner, N.; Holst, J. J.; Gutniak, M.; Hellström, P. M. Prandial subcutaneous injections of glucagon-like peptide-1 cause weight loss in obese human subjects. Br. J. Nutr. 2004, 91, 439-446.
    • (2004) Br. J. Nutr. , vol.91 , pp. 439-446
    • Nälund, E.1    King, N.2    Mansten, S.3    Adner, N.4    Holst, J.J.5    Gutniak, M.6    Hellström, P.M.7
  • 52
    • 0037045845 scopus 로고    scopus 로고
    • Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: A parallel-group study
    • Zander, M.; Madsbad, S.; Madsen, J. L.; Hoist, J. J. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet 2002, 359, 824-830.
    • (2002) Lancet , vol.359 , pp. 824-830
    • Zander, M.1    Madsbad, S.2    Madsen, J.L.3    Hoist, J.J.4
  • 53
    • 19344374606 scopus 로고    scopus 로고
    • Evaluation of interactions between CCK and GLP-1 in their effects on appetite, energy intake, and antropyloroduodenal motility in healthy men
    • Brennan, I. M.; Feltrin, K. L.; Horowitz, M.; Smout, A. J. P., M.; Meyer, J. H.; Wishart, J.; Feinle, B., C. Evaluation of interactions between CCK and GLP-1 in their effects on appetite, energy intake, and antropyloroduodenal motility in healthy men. Am. J. Physiol. 2005, 288, R1477-R1485.
    • (2005) Am. J. Physiol. , vol.288
    • Brennan, I.M.1    Feltrin, K.L.2    Horowitz, M.3    Smout, A.J.P.M.4    Meyer, J.H.5    Wishart, J.6    Feinle, B.C.7
  • 54
    • 4243638562 scopus 로고
    • Motility of the small intestine
    • 2 ed.; Lippincott, J. B.: Philadelphia
    • Hasler, W. L. Motility of the small intestine. Textbook of Gastroenterology; 2 ed.; Lippincott, J. B.: Philadelphia, 1995; pp. 207-233.
    • (1995) Textbook of Gastroenterology , pp. 207-233
    • Hasler, W.L.1
  • 55
    • 0037096140 scopus 로고    scopus 로고
    • Glucagon-like peptide-1 analogue LY315902: Effect on intestinal motility and release of insulin and somatostatin
    • Näslund, E.; Skogar, S.; Efendic, S.; Hellström, P. M. Glucagon-like peptide-1 analogue LY315902: Effect on intestinal motility and release of insulin and somatostatin. Regul. Pept. 2002, 106, 89-95.
    • (2002) Regul. Pept. , vol.106 , pp. 89-95
    • Näslund, E.1    Skogar, S.2    Efendic, S.3    Hellström, P.M.4
  • 56
    • 15044340837 scopus 로고    scopus 로고
    • The physiological role of GLP-1 in human: Incretin, ileal brake or more?
    • Schirra, J.; Göke, B. The physiological role of GLP-1 in human: incretin, ileal brake or more? Regul. Pept. 2005, 128, 109-115.
    • (2005) Regul. Pept. , vol.128 , pp. 109-115
    • Schirra, J.1    Göke, B.2
  • 58
    • 0035851852 scopus 로고    scopus 로고
    • Interactions between gastric emptying and satiety, with special reference to glucagon-like peptide-1
    • Hellström, P. M.; Näslund, E. Interactions between gastric emptying and satiety, with special reference to glucagon-like peptide-1. Physiol. Behav. 2001, 74, 735-741.
    • (2001) Physiol. Behav. , vol.74 , pp. 735-741
    • Hellström, P.M.1    Näslund, E.2
  • 61
    • 0031964636 scopus 로고    scopus 로고
    • Intraventricular GLP-1 reduces short- but not long-term food intake or body weight in lean and obese rats
    • Donahey, J. C. K.; Van, D., G.; Woods, S. C.; Seeley, R. J. Intraventricular GLP-1 reduces short- but not long-term food intake or body weight in lean and obese rats. Brain Res. 1998, 779, 75-83.
    • (1998) Brain Res. , vol.779 , pp. 75-83
    • Donahey, J.C.K.1    Van, D.G.2    Woods, S.C.3    Seeley, R.J.4
  • 65
    • 18144381593 scopus 로고    scopus 로고
    • The inhibitory effects of peripheral administration of peptide YY (3-36) and glucagon-like peptide-1 on food intake are attenuated by ablation of the vagal-brainstem-hypothalamic pathway
    • Abbott; C. R.; Monteiro, M.; Small, C. J.; Sajedi, A.; Smith, K. L.; Parkinson, J. R., C; Ghatei, M. A.; Bloom, S. R. The inhibitory effects of peripheral administration of peptide YY (3-36) and glucagon-like peptide-1 on food intake are attenuated by ablation of the vagal-brainstem-hypothalamic pathway. Brain Res. 2005, 1044, 127-131.
    • (2005) Brain Res. , vol.1044 , pp. 127-131
    • Abbott, C.R.1    Monteiro, M.2    Small, C.J.3    Sajedi, A.4    Smith, K.L.5    Parkinson, J.R.C.6    Ghatei, M.A.7    Bloom, S.R.8
  • 68
    • 0032966882 scopus 로고    scopus 로고
    • Glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2
    • Gutzwiller, J. P.; Drewe, J.; Goke, B.; Schmidt, H.; Rohrer, B.; Lareida, J.; Beglinger, C. Glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2. Am. J. Physiol. 1999, 276, R1541-R1544.
    • (1999) Am. J. Physiol. , vol.276
    • Gutzwiller, J.P.1    Drewe, J.2    Goke, B.3    Schmidt, H.4    Rohrer, B.5    Lareida, J.6    Beglinger, C.7
  • 69
    • 0032976939 scopus 로고    scopus 로고
    • Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients
    • Toft-Nielsen, M. B.; Madsbad, S.; Hoist, J. J. Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients. Diabetes Care 1999, 22, 1137-1143.
    • (1999) Diabetes Care , vol.22 , pp. 1137-1143
    • Toft-Nielsen, M.B.1    Madsbad, S.2    Hoist, J.J.3
  • 70
    • 0141669196 scopus 로고    scopus 로고
    • Effects of 3 months of continuous subcutaneous administration of glucagon-like peptide 1 in elderly patients with type 2 diabetes
    • Meneilly, G. S.; Greig, N.; Tildesley, H.; Habener, J. F.; Egan, J. M.; Elahi, D. Effects of 3 months of continuous subcutaneous administration of glucagon-like peptide 1 in elderly patients with type 2 diabetes. Diabetes Care 2003, 26, 2835-2841.
    • (2003) Diabetes Care , vol.26 , pp. 2835-2841
    • Meneilly, G.S.1    Greig, N.2    Tildesley, H.3    Habener, J.F.4    Egan, J.M.5    Elahi, D.6
  • 71
    • 22644444292 scopus 로고    scopus 로고
    • Effects of liraglutide NN2211, a long-acting GLP-1 analogue, on glycaemic control and bodyweight in subjects with Type 2 diabetes
    • Feinglos, M. N.; Saad, M. F.; Pi-Sunyer, F. X.; An, B.; Santiago, O. Effects of liraglutide NN2211, a long-acting GLP-1 analogue, on glycaemic control and bodyweight in subjects with Type 2 diabetes. Diabet. Med. 2005, 22, 1016-1023.
    • (2005) Diabet. Med. , vol.22 , pp. 1016-1023
    • Feinglos, M.N.1    Saad, M.F.2    Pi-Sunyer, F.X.3    An, B.4    Santiago, O.5
  • 72
    • 3342984674 scopus 로고    scopus 로고
    • The effect of liraglutide, a long-acting glucagon-like peptide 1 derivative, on glycemic control, body composition, and 24-h energy expenditure in patients with type 2 diabetes
    • Harder, H.; Nielsen, L.; Tu, D. T., Thi; Astrup, A. The effect of liraglutide, a long-acting glucagon-like peptide 1 derivative, on glycemic control, body composition, and 24-h energy expenditure in patients with type 2 diabetes. Diabetes Care 2004, 27, 1915-1921.
    • (2004) Diabetes Care , vol.27 , pp. 1915-1921
    • Harder, H.1    Nielsen, L.2    Tu, D.T.3    Thi4    Astrup, A.5
  • 73
    • 2542451393 scopus 로고    scopus 로고
    • Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide NN2211: A 12-week, double-blind, randomized, controlled trial
    • Madsbad, S.; Schmitz, O.; Ranstam, J.; Jakobsen, G.; Matthews, D. R. Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide NN2211: a 12-week, double-blind, randomized, controlled trial. Diabetes Care 2004, 27, 1335-1342.
    • (2004) Diabetes Care , vol.27 , pp. 1335-1342
    • Madsbad, S.1    Schmitz, O.2    Ranstam, J.3    Jakobsen, G.4    Matthews, D.R.5
  • 74
    • 2342599057 scopus 로고    scopus 로고
    • One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide NN2211 markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes
    • Degn, K. B.; Juhl, C. B.; Sturis, J.; Jakobsen, G.; Brock, B.; Chandramouli, V.; Rungby, J.; Landau, B., R.; Schmitz, O. One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide NN2211 markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes. Diabetes 2004, 53, 1187-1194.
    • (2004) Diabetes , vol.53 , pp. 1187-1194
    • Degn, K.B.1    Juhl, C.B.2    Sturis, J.3    Jakobsen, G.4    Brock, B.5    Chandramouli, V.6    Rungby, J.7    Landau, B.R.8    Schmitz, O.9
  • 76
    • 2542479964 scopus 로고    scopus 로고
    • Minireview: Gut peptides regulating satiety
    • Druce, M. R.; Small, C. J.; Bloom, S. R. Minireview: Gut peptides regulating satiety. Endocrinology 2004, 145, 2660-2665.
    • (2004) Endocrinology , vol.145 , pp. 2660-2665
    • Druce, M.R.1    Small, C.J.2    Bloom, S.R.3
  • 77
    • 1942487860 scopus 로고    scopus 로고
    • Gastrointestinal Satiety Signals III. Glucagon-like peptide 1, oxyntomodulin, peptide YY, and pancreatic polypeptide
    • Stanley, S.; Wynne, K.; Bloom, S. Gastrointestinal Satiety Signals III. Glucagon-like peptide 1, oxyntomodulin, peptide YY, and pancreatic polypeptide. Am. J. Physiol. 2004, 286, G693-G697.
    • (2004) Am. J. Physiol. , vol.286
    • Stanley, S.1    Wynne, K.2    Bloom, S.3
  • 78
    • 0038363769 scopus 로고    scopus 로고
    • Implementation of GLP-1 based therapy of type 2 diabetes mellitus using DPP-IV inhibitors
    • Holst, J. J. Implementation of GLP-1 based therapy of type 2 diabetes mellitus using DPP-IV inhibitors. Adv. Exp. Med. Biol. 2003, 524, 263-279.
    • (2003) Adv. Exp. Med. Biol. , vol.524 , pp. 263-279
    • Holst, J.J.1
  • 80
    • 0036312876 scopus 로고    scopus 로고
    • Chronic inhibition of circulating dipeptidyl peptidase IV by FE 999011 delays the occurrence of diabetes in male Zucker diabetic fatty rats
    • Sudre, B.; Broqua, P.; White, R. B.; Ashworth, D.; Evans, D. M.; Haigh, R.; Junien, J. L.; Aubert, M. L. Chronic inhibition of circulating dipeptidyl peptidase IV by FE 999011 delays the occurrence of diabetes in male Zucker diabetic fatty rats. Diabetes 2002, 51, 1461-1469.
    • (2002) Diabetes , vol.51 , pp. 1461-1469
    • Sudre, B.1    Broqua, P.2    White, R.B.3    Ashworth, D.4    Evans, D.M.5    Haigh, R.6    Junien, J.L.7    Aubert, M.L.8
  • 81
    • 2442482515 scopus 로고    scopus 로고
    • Inhibition of Dipeptidyl Peptidase-4 Reduces Glycemia, Sustains Insulin Levels, and Reduces Glucagon Levels in Type 2 Diabetes
    • Ahrén, B.; Landin, O., M.; Jansson, P. A.; Svensson, M.; Holmes, D.; Schweizer, A. Inhibition of Dipeptidyl Peptidase-4 Reduces Glycemia, Sustains Insulin Levels, and Reduces Glucagon Levels in Type 2 Diabetes. J. Clin. Endocrinol. Metab. 2004, 89, 2078-2084.
    • (2004) J. Clin. Endocrinol. Metab. , vol.89 , pp. 2078-2084
    • Ahrén, B.1    Landin, O.M.2    Jansson, P.A.3    Svensson, M.4    Holmes, D.5    Schweizer, A.6
  • 83
    • 27744540889 scopus 로고    scopus 로고
    • Improved glycaemic control with dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes: Vildagliptin (LAF237) dose response
    • Ristic, S.; Byiers, S.; Foley, J.; Holmes, D. improved glycaemic control with dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes: Vildagliptin (LAF237) dose response. Diabetes Obes. Metab. 2005, 7, 692-698.
    • (2005) Diabetes Obes. Metab. , vol.7 , pp. 692-698
    • Ristic, S.1    Byiers, S.2    Foley, J.3    Holmes, D.4
  • 84
    • 9444285818 scopus 로고    scopus 로고
    • Twelve-and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes
    • Ahrén, B.; Gomis, R.; Standl, E.; Mills, D.; Schweizer, A. Twelve-and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes. Diabetes Care 2004, 27, 2874-2880.
    • (2004) Diabetes Care , vol.27 , pp. 2874-2880
    • Ahrén, B.1    Gomis, R.2    Standl, E.3    Mills, D.4    Schweizer, A.5
  • 86
    • 0037370995 scopus 로고    scopus 로고
    • Glucagon-like peptide 2 function in domestic animals
    • Burrin, D. G.; Stoll, B.; Guan, X. Glucagon-like peptide 2 function in domestic animals. Domest. Anim. Endocrinol. 2003, 24, 103-122.
    • (2003) Domest. Anim. Endocrinol. , vol.24 , pp. 103-122
    • Burrin, D.G.1    Stoll, B.2    Guan, X.3
  • 87
    • 0035097144 scopus 로고    scopus 로고
    • Glucagon-like peptide 2: A nutrient-responsive gut growth factor
    • Burrin, D. G.; Petersen, Y.; Stoll, B.; Sangild, P. Glucagon-like peptide 2: A nutrient-responsive gut growth factor. J. Nutr. 2001, 131, 709-712.
    • (2001) J. Nutr. , vol.131 , pp. 709-712
    • Burrin, D.G.1    Petersen, Y.2    Stoll, B.3    Sangild, P.4
  • 88
    • 0037898380 scopus 로고    scopus 로고
    • Diabetic dyslipidaemia: From basic research to clinical practice
    • Taskinen, M. R. Diabetic dyslipidaemia: from basic research to clinical practice. Diabetologia 2003, 733-749.
    • Diabetologia , vol.2003 , pp. 733-749
    • Taskinen, M.R.1
  • 89
    • 0029741921 scopus 로고    scopus 로고
    • A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction
    • Stampfer, M. J.; Krauss, R. M.; Ma, J.; Blanche, P. J.; Holl, L. G.; Sacks, F. M.; Hennekens, C. H. A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction. JAMA 1996, 276, 882-888.
    • (1996) JAMA , vol.276 , pp. 882-888
    • Stampfer, M.J.1    Krauss, R.M.2    Ma, J.3    Blanche, P.J.4    Holl, L.G.5    Sacks, F.M.6    Hennekens, C.H.7
  • 93
    • 0142074274 scopus 로고    scopus 로고
    • GLP-1 stimulates glucose-derived de novo fatty acid synthesis and chain elongation during cell differentiation and insulin release
    • Bulotta, A.; Perfetti, R.; Hui, H.; Boros, L. G. GLP-1 stimulates glucose-derived de novo fatty acid synthesis and chain elongation during cell differentiation and insulin release. J. Lipid Res. 2003, 44, 1559-1565.
    • (2003) J. Lipid Res. , vol.44 , pp. 1559-1565
    • Bulotta, A.1    Perfetti, R.2    Hui, H.3    Boros, L.G.4
  • 94
    • 23844526330 scopus 로고    scopus 로고
    • Effects of glucagon-like peptide-1 and exendins on kinase activity, glucose transport and lipid metabolism in adipocytes from normal and type-2 diabetic rats
    • Sancho, V.; Trigo, M. V.; González, N.; Valverde, I.; Malaisse, W. J.; Villanueva Peñacarrillo, M. L. Effects of glucagon-like peptide-1 and exendins on kinase activity, glucose transport and lipid metabolism in adipocytes from normal and type-2 diabetic rats. J. Mol. Endocrinol. 2005, 35, 27-38.
    • (2005) J. Mol. Endocrinol. , vol.35 , pp. 27-38
    • Sancho, V.1    Trigo, M.V.2    González, N.3    Valverde, I.4    Malaisse, W.J.5    Villanueva Peñacarrillo, M.L.6
  • 95
    • 0034011021 scopus 로고    scopus 로고
    • The effect of glucagon-like peptide-1 on energy expenditure and substrate metabolism in humans
    • Flint, A.; Raben, A.; Rehfeld, J. F.; Holst, J. J.; Astrup, A. The effect of glucagon-like peptide-1 on energy expenditure and substrate metabolism in humans. Int. J. Obesity 2000, 24, 288-298.
    • (2000) Int. J. Obesity , vol.24 , pp. 288-298
    • Flint, A.1    Raben, A.2    Rehfeld, J.F.3    Holst, J.J.4    Astrup, A.5
  • 96
    • 0027157849 scopus 로고
    • Biological effects and metabolic rates of glucagonlike peptide-1 7-36 amide and glucagonlike peptide-1 7-37 in healthy subjects are indistinguishable
    • Orskov, C.; Wettergren, A.; Holst, J. J. Biological effects and metabolic rates of glucagonlike peptide-1 7-36 amide and glucagonlike peptide-1 7-37 in healthy subjects are indistinguishable. Diabetes 1993, 42, 658-661.
    • (1993) Diabetes , vol.42 , pp. 658-661
    • Orskov, C.1    Wettergren, A.2    Holst, J.J.3
  • 97
    • 17644373076 scopus 로고    scopus 로고
    • GLP-1 reduces intestinal lymph flow, triglyceride absorption, and apolipoprotein production in rats
    • Qin, X.; Shen, H.; Liu, M.; Yang, Q.; Zheng, S.; Sabo, M.; D'Alessio, D. A.; Tso, P. GLP-1 reduces intestinal lymph flow, triglyceride absorption, and apolipoprotein production in rats. Am. J. Physiol. 2005, 288, G943-G949.
    • (2005) Am. J. Physiol. , vol.288
    • Qin, X.1    Shen, H.2    Liu, M.3    Yang, Q.4    Zheng, S.5    Sabo, M.6    D'Alessio, D.A.7    Tso, P.8
  • 98
    • 0029857454 scopus 로고    scopus 로고
    • The antidiabetogenic effect of GLP-1 is maintained during a 7-day treatment period and improves diabetic dyslipoproteinemia in NIDDM patients
    • Juntti, B. L.; Pigon, J.; Karpe, F.; Hamsten, A.; Gutniak, M.; Vignati, L.; Efendic, S. The antidiabetogenic effect of GLP-1 is maintained during a 7-day treatment period and improves diabetic dyslipoproteinemia in NIDDM patients. Diabetes Care 1996, 19, 1200-1206.
    • (1996) Diabetes Care , vol.19 , pp. 1200-1206
    • Juntti, B.L.1    Pigon, J.2    Karpe, F.3    Hamsten, A.4    Gutniak, M.5    Vignati, L.6    Efendic, S.7
  • 99
    • 3342971029 scopus 로고    scopus 로고
    • Additive effects of glucagon-fike peptide 1 and pioglitazone in patients with type 2 diabetes
    • Zander, M.; Christiansen, A.; Madsbad, S.; Holst, J. J. Additive effects of glucagon-fike peptide 1 and pioglitazone in patients with type 2 diabetes. Diabetes Care 2004, 27, 1910-1914.
    • (2004) Diabetes Care , vol.27 , pp. 1910-1914
    • Zander, M.1    Christiansen, A.2    Madsbad, S.3    Holst, J.J.4
  • 100
    • 0018672563 scopus 로고
    • Gastric inhibitory polypeptide enhanced lipoprotein lipase activity in cultured preadipocytes
    • Eckel, R. H.; Fujimoto, W. Y.; Brunzell, J. D. Gastric inhibitory polypeptide enhanced lipoprotein lipase activity in cultured preadipocytes. Diabetes 1979, 28, 1141-1142.
    • (1979) Diabetes , vol.28 , pp. 1141-1142
    • Eckel, R.H.1    Fujimoto, W.Y.2    Brunzell, J.D.3
  • 101
    • 0031730586 scopus 로고    scopus 로고
    • Functional GIP receptors are present on adipocytes
    • Yip, R. G. C.; Boylan, M. O.; Kieffer, T. J.; Wolfe, M. M. Functional GIP receptors are present on adipocytes. Endocrinology 1998, 139, 4004-4007.
    • (1998) Endocrinology , vol.139 , pp. 4004-4007
    • Yip, R.G.C.1    Boylan, M.O.2    Kieffer, T.J.3    Wolfe, M.M.4
  • 102
    • 0032895556 scopus 로고    scopus 로고
    • Glucose-dependent insulinotropic polypeptide stimulation of lipolysis in differentiated 3T3-L1 cells: Wortmannin-sensitive inhibition by insulin
    • McIntosh, C. H. S.; Bremsak, I.; Lynn, F. C.; Gill, R.; Hinke, S. A.; Gelling, R.; Nian, C.; McKnight, G.; Jaspers, S.; Pederson, R. A. Glucose-dependent insulinotropic polypeptide stimulation of lipolysis in differentiated 3T3-L1 cells: Wortmannin-sensitive inhibition by insulin. Endocrinology 1999, 140, 398-404.
    • (1999) Endocrinology , vol.140 , pp. 398-404
    • McIntosh, C.H.S.1    Bremsak, I.2    Lynn, F.C.3    Gill, R.4    Hinke, S.A.5    Gelling, R.6    Nian, C.7    McKnight, G.8    Jaspers, S.9    Pederson, R.A.10
  • 103
    • 0033817531 scopus 로고    scopus 로고
    • Effects of gastric inhibitory polypeptide, somatostatin and epidermal growth factor on lipogenesis in ovine adipose explants
    • Baba, A. S. H.; Harper, J. M. M.; Buttery, P. J. Effects of gastric inhibitory polypeptide, somatostatin and epidermal growth factor on lipogenesis in ovine adipose explants. Comp. Biochem. Physiol., Part B: Biochem. Mol. Biol. 2000, 127, 173-182.
    • (2000) Comp. Biochem. Physiol., Part B: Biochem. Mol. Biol. , vol.127 , pp. 173-182
    • Baba, A.S.H.1    Harper, J.M.M.2    Buttery, P.J.3
  • 104
    • 0024271044 scopus 로고
    • Effects of gastric inhibitory polypeptide on glucose and lipid metabolism of isolated rat adipocytes
    • Hauner, H.; Glatting, G.; Kaminska, D.; Pfeiffer, E. F. Effects of gastric inhibitory polypeptide on glucose and lipid metabolism of isolated rat adipocytes. Ann. Nutr. Metab. 1988, 32, 282-288.
    • (1988) Ann. Nutr. Metab. , vol.32 , pp. 282-288
    • Hauner, H.1    Glatting, G.2    Kaminska, D.3    Pfeiffer, E.F.4
  • 105
    • 0026534074 scopus 로고
    • Effects of gastro-entero-pancreatic hormones upon triglyceride synthesis and secretion by rat hepatocytes
    • Wolfe, B. M. Effects of gastro-entero-pancreatic hormones upon triglyceride synthesis and secretion by rat hepatocytes. Clin. Invest. Med. 1992, 15, 30-41.
    • (1992) Clin. Invest. Med. , vol.15 , pp. 30-41
    • Wolfe, B.M.1
  • 106
    • 0025750777 scopus 로고
    • Effect of exogenous or endogenous gastric inhibitory polypeptide (GIP) on plasma triglyceride responses in rats
    • Ebert, R.; Nauck, M.; Creutzfeldt, W. Effect of exogenous or endogenous gastric inhibitory polypeptide (GIP) on plasma triglyceride responses in rats. Horm. Metab. Res. 1991, 23, 517-521.
    • (1991) Horm. Metab. Res. , vol.23 , pp. 517-521
    • Ebert, R.1    Nauck, M.2    Creutzfeldt, W.3
  • 107
    • 0019407932 scopus 로고
    • Effect of gastric inhibitory polypeptide on plasma levels of chylomicron triglycerides in dogs
    • Wasada, T.; McCorkle, K.; Harris, V. Effect of gastric inhibitory polypeptide on plasma levels of chylomicron triglycerides in dogs. J. Clin. Invest. 1981, 68, 1106-1107.
    • (1981) J. Clin. Invest. , vol.68 , pp. 1106-1107
    • Wasada, T.1    McCorkle, K.2    Harris, V.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.